stockrowPalvella Therapeutics, Inc.
PVLA Healthcare Biotechnology
Palvella Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $25.9 million.
- EPS
- −76.7%
- Free cash flow
- −136.4%
Quarter to June 2026, against a year earlier
Follow PVLA
Alert me
Palvella Therapeutics, Inc. (PVLA) Current ratio
Palvella Therapeutics, Inc.'s current ratio at the end of the quarter to 30 June 2026 was 21.2×, up 16.0× from fiscal 2025 (5.2×). Over the past ten years it has ranged from 2.0× (fiscal 2017) to 11.3× (fiscal 2015); the current reading is higher than 82% of that period. That is above the Biotechnology industry median of 4.9× and above the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 5.2× | (29.06%) |
| FY2024 | 7.3× | 129.17% |
| FY2023 | 3.2× | 59.35% |
| FY2022 | 2.0× | (20.49%) |
| FY2021 | 2.5× | (26.18%) |
| FY2020 | 3.4× | (19.72%) |
| FY2019 | 4.3× | 51.25% |
| FY2018 | 2.8× | 43.56% |
| FY2017 | 2.0× | (49.69%) |
| FY2016 | 3.9× | (65.54%) |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Jun 2026 | 21.2× | (26.66%) |
| Mar 2026 | 28.9× | 455.38% |
| Dec 2025 | 5.2× | (19.89%) |
| Sep 2025 | 6.5× | (15.36%) |
| 42 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| PVLA Palvella Therapeutics, Inc. | 21.2× |
| IMNM Immunome, Inc. compare | 15.1× |
| PHVS Pharvaris N.V. compare | 11.9× |
| CLDX Celldex Therapeutics, Inc. compare | 11.8× |
| VERA Vera Therapeutics, Inc. compare | 10.9× |
| AUPH Aurinia Pharmaceuticals Inc compare | 6.1× |
| ADMA ADMA Biologics Inc compare | 6.0× |
| VCEL Vericel Corporation compare | 5.1× |
| BHVN Biohaven Ltd. compare | 3.1× |
| Biotechnology industry median | 4.9× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on PVLA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement